These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

734 related articles for article (PubMed ID: 26378168)

  • 1. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.
    Kaneko M; Watashi K; Kamisuki S; Matsunaga H; Iwamoto M; Kawai F; Ohashi H; Tsukuda S; Shimura S; Suzuki R; Aizaki H; Sugiyama M; Park SY; Ito T; Ohtani N; Sugawara F; Tanaka Y; Mizokami M; Sureau C; Wakita T
    J Virol; 2015 Dec; 89(23):11945-53. PubMed ID: 26378168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide.
    Yan H; Peng B; Liu Y; Xu G; He W; Ren B; Jing Z; Sui J; Li W
    J Virol; 2014 Mar; 88(6):3273-84. PubMed ID: 24390325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and D virus.
    Yan H; Li W
    Dig Dis; 2015; 33(3):388-96. PubMed ID: 26045274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.
    Ni Y; Lempp FA; Mehrle S; Nkongolo S; Kaufman C; Fälth M; Stindt J; Königer C; Nassal M; Kubitz R; Sültmann H; Urban S
    Gastroenterology; 2014 Apr; 146(4):1070-83. PubMed ID: 24361467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.
    Nkongolo S; Ni Y; Lempp FA; Kaufman C; Lindner T; Esser-Nobis K; Lohmann V; Mier W; Mehrle S; Urban S
    J Hepatol; 2014 Apr; 60(4):723-31. PubMed ID: 24295872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical array system, a platform to identify novel hepatitis B virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide.
    Kaneko M; Futamura Y; Tsukuda S; Kondoh Y; Sekine T; Hirano H; Fukano K; Ohashi H; Saso W; Morishita R; Matsunaga S; Kawai F; Ryo A; Park SY; Suzuki R; Aizaki H; Ohtani N; Sureau C; Wakita T; Osada H; Watashi K
    Sci Rep; 2018 Feb; 8(1):2769. PubMed ID: 29426822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity.
    Shimura S; Watashi K; Fukano K; Peel M; Sluder A; Kawai F; Iwamoto M; Tsukuda S; Takeuchi JS; Miyake T; Sugiyama M; Ogasawara Y; Park SY; Tanaka Y; Kusuhara H; Mizokami M; Sureau C; Wakita T
    J Hepatol; 2017 Apr; 66(4):685-692. PubMed ID: 27890789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NTCP opens the door for hepatitis B virus infection.
    Yan H; Liu Y; Sui J; Li W
    Antiviral Res; 2015 Sep; 121():24-30. PubMed ID: 26071008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP.
    Iwamoto M; Watashi K; Tsukuda S; Aly HH; Fukasawa M; Fujimoto A; Suzuki R; Aizaki H; Ito T; Koiwai O; Kusuhara H; Wakita T
    Biochem Biophys Res Commun; 2014 Jan; 443(3):808-13. PubMed ID: 24342612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP.
    Donkers JM; Zehnder B; van Westen GJP; Kwakkenbos MJ; IJzerman AP; Oude Elferink RPJ; Beuers U; Urban S; van de Graaf SFJ
    Sci Rep; 2017 Nov; 7(1):15307. PubMed ID: 29127322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes.
    König A; Döring B; Mohr C; Geipel A; Geyer J; Glebe D
    J Hepatol; 2014 Oct; 61(4):867-75. PubMed ID: 24845614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP).
    Watashi K; Sluder A; Daito T; Matsunaga S; Ryo A; Nagamori S; Iwamoto M; Nakajima S; Tsukuda S; Borroto-Esoda K; Sugiyama M; Tanaka Y; Kanai Y; Kusuhara H; Mizokami M; Wakita T
    Hepatology; 2014 May; 59(5):1726-37. PubMed ID: 24375637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new strategy to identify hepatitis B virus entry inhibitors by AlphaScreen technology targeting the envelope-receptor interaction.
    Saso W; Tsukuda S; Ohashi H; Fukano K; Morishita R; Matsunaga S; Ohki M; Ryo A; Park SY; Suzuki R; Aizaki H; Muramatsu M; Sureau C; Wakita T; Matano T; Watashi K
    Biochem Biophys Res Commun; 2018 Jun; 501(2):374-379. PubMed ID: 29730285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTCP Oligomerization Occurs Downstream of the NTCP-EGFR Interaction during Hepatitis B Virus Internalization.
    Fukano K; Oshima M; Tsukuda S; Aizaki H; Ohki M; Park SY; Wakita T; Wakae K; Watashi K; Muramatsu M
    J Virol; 2021 Nov; 95(24):e0093821. PubMed ID: 34613794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP).
    Veloso Alves Pereira I; Buchmann B; Sandmann L; Sprinzl K; Schlaphoff V; Döhner K; Vondran F; Sarrazin C; Manns MP; Pinto Marques Souza de Oliveira C; Sodeik B; Ciesek S; von Hahn T
    PLoS One; 2015; 10(2):e0117152. PubMed ID: 25646622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus.
    Yan H; Zhong G; Xu G; He W; Jing Z; Gao Z; Huang Y; Qi Y; Peng B; Wang H; Fu L; Song M; Chen P; Gao W; Ren B; Sun Y; Cai T; Feng X; Sui J; Li W
    Elife; 2012 Nov; 3():. PubMed ID: 25409679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a mass spectrometric screening assay for hepatitis B virus entry inhibitors.
    Goh B; Choi J; Kang JA; Park SG; Seo J; Kim TY
    J Pharm Biomed Anal; 2020 Jan; 178():112959. PubMed ID: 31722821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets.
    Yu Y; Li S; Liang W
    Emerg Microbes Infect; 2018 Jul; 7(1):134. PubMed ID: 30050063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies to inhibit entry of HBV and HDV into hepatocytes.
    Urban S; Bartenschlager R; Kubitz R; Zoulim F
    Gastroenterology; 2014 Jul; 147(1):48-64. PubMed ID: 24768844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression.
    Tsukuda S; Watashi K; Iwamoto M; Suzuki R; Aizaki H; Okada M; Sugiyama M; Kojima S; Tanaka Y; Mizokami M; Li J; Tong S; Wakita T
    J Biol Chem; 2015 Feb; 290(9):5673-84. PubMed ID: 25550158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.